
Sign up to save your podcasts
Or


This is the latest episode of the free DDW narrated podcast, titled "Innovative uses for biomarkers in drug discovery", which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: "Advances in neuroscience drug discovery", "Putting human data at the centre of drug discovery", and "The era of precision neuroscience".
In the first article, Lu Rahman looks at neuroscience drug discovery – advances and challenges – and how breakthroughs in this field are helping address areas of unmet need.
In the second article, James Peach, Co-Founder and CEO of Human Centric Drug Discovery (HCDD), an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process, shares insight with me.
In the third article, Dr Steve Gardner, CEO of the computational biology company PrecisionLife, explores the challenges of achieving precision medicine in complex CNS conditions and explains how new precision neuroscience approaches are benefitting pharmaceutical companies who are again investing in the field to develop better treatments for neurological and neuropsychiatric diseases.
By Drug Discovery World (DDW)3.5
2020 ratings
This is the latest episode of the free DDW narrated podcast, titled "Innovative uses for biomarkers in drug discovery", which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: "Advances in neuroscience drug discovery", "Putting human data at the centre of drug discovery", and "The era of precision neuroscience".
In the first article, Lu Rahman looks at neuroscience drug discovery – advances and challenges – and how breakthroughs in this field are helping address areas of unmet need.
In the second article, James Peach, Co-Founder and CEO of Human Centric Drug Discovery (HCDD), an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process, shares insight with me.
In the third article, Dr Steve Gardner, CEO of the computational biology company PrecisionLife, explores the challenges of achieving precision medicine in complex CNS conditions and explains how new precision neuroscience approaches are benefitting pharmaceutical companies who are again investing in the field to develop better treatments for neurological and neuropsychiatric diseases.

43,680 Listeners

7,683 Listeners

4,175 Listeners

765 Listeners

166 Listeners

403 Listeners

824 Listeners

112,358 Listeners

56,692 Listeners

321 Listeners

639 Listeners

66 Listeners

794 Listeners

85 Listeners

21 Listeners